Physician profile
Vineet Puri
NPI 1548215981
$2,824.29
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.79 · 2020: $186 · 2021: $1,435 · 2022: $272 · 2023: $405 · 2024: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $982.27 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $339.29 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $305.26 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $215.30 | 2019-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $201.02 | 2021-2024 | |
| Glaxosmithkline, LLC. | $150.37 | 2020-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $86.99 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $60.59 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $59.60 | 2023 | Quviviq |
| Pfizer INC. | $57.67 | 2019-2023 | |
| Dexcom, INC. | $53.54 | 2021-2022 | |
| Astellas Pharma US INC | $52.06 | 2021-2023 | Veozah |
| Abbott Laboratories | $44.25 | 2024 | Proclaim, Freestyle Libre 3 |
| Merz North America, INC. | $36.47 | 2023 | Xeomin |
| Tactile Systems Technology INC | $28.60 | 2024 | Flexitouch Plus, Entre Plus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $23.80 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $18.82 | 2022 | |
| G Medical Diagnostic Services, INC. | $18.01 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.67 | 2019 | |
| Exact Sciences Corporation | $17.49 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $15.48 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.70 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.98 | 2023 | Stiolto Respimat |
| Eisai INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineet Puri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.